Advertisement
Screener

ARVINAS, INC. (ARVN) Overview

ARVINAS, INC. (ARVN) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 2.58; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.90; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.48; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.84; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$6.08$7.24$8.61$10.25$12.20$14.522025-11-062026-11-06$5.77$10.15$17.87$31.46$55.37$97.472021-11-082026-11-06$5.77$10.46$18.98$34.42$62.44$113.262018-09-272026-11-06$5.77$10.46$18.98$34.42$62.44$113.262018-09-272026-11-06$5.77$10.46$18.98$34.42$62.44$113.262018-09-272026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$6.40
Previous close
$7.50
Change
-$1.10
Change (%)
-14.67%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

ARVN
-36.76%
S&P 500
(m)

1 year

ARVN
-12.08%
S&P 500
(m)

3 years

ARVN
-61.81%
S&P 500
(m)

5 years

ARVN
-90.92%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 2.58

-0.98-0.040.891.832.7631 Mar 2025: estimate (m); actual 1.1431 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.8430 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.4830 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.9031 Mar 2026(m)30 Jun 2026: estimate (m); actual 2.5830 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)2.58(m)(m)
1 Jan 202631 Mar 2026(m)-0.90(m)(m)
1 Jul 202530 Sept 2025(m)-0.48(m)(m)
1 Apr 202530 Jun 2025(m)-0.84(m)(m)
1 Jan 202531 Mar 2025(m)1.14(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -1.14

-6.70-5.27-3.83-2.40-0.9631 Dec 2021: estimate (m); actual -3.8231 Dec 2021(m)31 Dec 2022: estimate (m); actual -5.3131 Dec 2022(m)31 Dec 2023: estimate (m); actual -6.6231 Dec 2023(m)31 Dec 2024: estimate (m); actual -2.7731 Dec 2024(m)31 Dec 2025: estimate (m); actual -1.1431 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-1.14(m)(m)
1 Jan 202431 Dec 2024(m)-2.77(m)(m)
1 Jan 202331 Dec 2023(m)-6.62(m)(m)
1 Jan 202231 Dec 2022(m)-5.31(m)(m)
1 Jan 202131 Dec 2021(m)-3.82(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 249.70M ■ Earnings 169.40M — Profit margin 67.84%

-105.68M-712.6%25.47M-452.1%156.63M-191.6%287.78M68.8%30 Sept 2025: revenue 41.90M; earnings -35.10M; profit margin -83.77%30 Sept 202531 Dec 2025: revenue 9.50M*; earnings -67.60M*; profit margin -711.58%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 15.60M; earnings -57.60M; profit margin -369.23%31 Mar 202630 Jun 2026: revenue 249.70M; earnings 169.40M; profit margin 67.84%30 Jun 2026

31 Dec 2025 ■ Revenue 262.60M ■ Earnings -81.00M — Profit margin -30.85%

-442.65M-468.5%-182.08M-322.3%78.48M-176.1%339.05M-29.8%31 Dec 2022: revenue 131.40M; earnings -283.00M; profit margin -215.37%31 Dec 202231 Dec 2023: revenue 78.50M; earnings -367.00M; profit margin -467.52%31 Dec 202331 Dec 2024: revenue 263.40M; earnings -199.00M; profit margin -75.55%31 Dec 202431 Dec 2025: revenue 262.60M; earnings -81.00M; profit margin -30.85%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$6.40(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$6.40High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning ARVN

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$9.10M
Profit margin
2.87%
Return on assets · 12 month
1.15%
Index membership
(m)
Employees
246.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
852.75K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-11.87%*
Total return · month
-18.30%*
Total return · quarter
-9.53%*
Total return · half year
-25.74%*
Total return · year to date
-36.76%*
Total return · 1 year
-12.08%*
Total return · 3 years
-61.81%*
Total return · 5 years
-90.92%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$316.70M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
0.09%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

ARVINAS, INC. Overview

View more →

(m)

(m)

SEC CIK
1655759
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
395 WINCHESTER AVE, 5 SCIENCE PARK, NEW HAVEN, Connecticut, 06511, United States
Fiscal year end
1231
Phone
203-535-1456

Similar stocks

Stock NameCountryMarket CapPE Ratio
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
Evolus, Inc. (EOLS)United States$0.519B-13.32
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85